The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis

David M. Kim, Kristian L. Koszeghy, Rachel L. Badovinac, Toshihisa Kawai, Ikuko Hosokawa, T. Howard Howell, Nadeem Y. Karimbux

Research output: Contribution to journalArticle

Abstract

Background: Inflammatory and anti-inflammatory mediators may play a significant role in patients with gingivitis. The purpose of this study was to assess the short-term effects of the systemic administration of two different concentrations of aspirin (81 and 325 mg/day, by mouth) on clinical periodontal parameters and gingival crevicular fluid (GCF) levels of 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and interleukin (IL)-6 and -1 β in a sample of naturally occurring gingivitis patients. Methods: At day 0, after initial screening for entry, baseline periodontal parameters, including bleeding on probing (BOP), periodontal probing depths (PDs), and plaque index (PI) were measured, and GCF was sampled from 12 intrasulcular sites with filter paper strips for the measurement of six types of inflammatory and anti-inflammatory mediators using competitive enzyme immunoassay and enzyme-linked immunosorbent assay (prevalues). Forty-seven subjects were assigned randomly to one of three treatment groups: placebo (15 subjects); aspirin, 81 mg (16 subjects); and aspirin, 325 mg (16 subjects) once daily. On day 7, subjects were recalled for the measurement of periodontal parameters and collection of GCF samples for the measurement of six types of mediators (postvalues). Results: Changes in inflammatory and anti-inflammatory mediator levels were not statistically significant for any of the three treatment groups. However, when pre- and postvalues were compared in the subjects receiving aspirin, 325 mg, there was a negative trend in the relationship between 15-epi-L)(A4 and PGE2, whereas the relationship between LTB4 and PGE2 was, not as strong. This might indicate that the subjects responding to aspirin-mediated PGE2 suppression effects produced higher 15-epi-LXA4 in GCF than non-responders. No statistically significant differences in PD and PI between pre- and postvalues were found for any of the three treatment groups. However, the results demonstrated a significant increase in BOP when aspirin, 325 mg was compared to placebo (P4 implied that this recently discovered aspirin-dependent eicosanoid may be associated with the increased incidence of BOP observed in the subjects who received aspirin therapy.

Original languageEnglish (US)
Pages (from-to)1620-1626
Number of pages7
JournalJournal of Periodontology
Volume78
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Gingival Crevicular Fluid
Gingivitis
Aspirin
Anti-Inflammatory Agents
Dinoprostone
Leukotriene B4
Hemorrhage
Placebos
Eicosanoids
Therapeutics
Immunoenzyme Techniques
Interleukin-1
Mouth
Interleukin-6
Enzyme-Linked Immunosorbent Assay

Keywords

  • Aspirin
  • Gingival crevicular fluid
  • Gingivitis

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

Kim, D. M., Koszeghy, K. L., Badovinac, R. L., Kawai, T., Hosokawa, I., Howell, T. H., & Karimbux, N. Y. (2007). The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis. Journal of Periodontology, 78(8), 1620-1626. https://doi.org/10.1902/jop.2007.070011

The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis. / Kim, David M.; Koszeghy, Kristian L.; Badovinac, Rachel L.; Kawai, Toshihisa; Hosokawa, Ikuko; Howell, T. Howard; Karimbux, Nadeem Y.

In: Journal of Periodontology, Vol. 78, No. 8, 08.2007, p. 1620-1626.

Research output: Contribution to journalArticle

Kim, David M. ; Koszeghy, Kristian L. ; Badovinac, Rachel L. ; Kawai, Toshihisa ; Hosokawa, Ikuko ; Howell, T. Howard ; Karimbux, Nadeem Y. / The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis. In: Journal of Periodontology. 2007 ; Vol. 78, No. 8. pp. 1620-1626.
@article{c5741a74f96d414babd7a963a76072cf,
title = "The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis",
abstract = "Background: Inflammatory and anti-inflammatory mediators may play a significant role in patients with gingivitis. The purpose of this study was to assess the short-term effects of the systemic administration of two different concentrations of aspirin (81 and 325 mg/day, by mouth) on clinical periodontal parameters and gingival crevicular fluid (GCF) levels of 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and interleukin (IL)-6 and -1 β in a sample of naturally occurring gingivitis patients. Methods: At day 0, after initial screening for entry, baseline periodontal parameters, including bleeding on probing (BOP), periodontal probing depths (PDs), and plaque index (PI) were measured, and GCF was sampled from 12 intrasulcular sites with filter paper strips for the measurement of six types of inflammatory and anti-inflammatory mediators using competitive enzyme immunoassay and enzyme-linked immunosorbent assay (prevalues). Forty-seven subjects were assigned randomly to one of three treatment groups: placebo (15 subjects); aspirin, 81 mg (16 subjects); and aspirin, 325 mg (16 subjects) once daily. On day 7, subjects were recalled for the measurement of periodontal parameters and collection of GCF samples for the measurement of six types of mediators (postvalues). Results: Changes in inflammatory and anti-inflammatory mediator levels were not statistically significant for any of the three treatment groups. However, when pre- and postvalues were compared in the subjects receiving aspirin, 325 mg, there was a negative trend in the relationship between 15-epi-L)(A4 and PGE2, whereas the relationship between LTB4 and PGE2 was, not as strong. This might indicate that the subjects responding to aspirin-mediated PGE2 suppression effects produced higher 15-epi-LXA4 in GCF than non-responders. No statistically significant differences in PD and PI between pre- and postvalues were found for any of the three treatment groups. However, the results demonstrated a significant increase in BOP when aspirin, 325 mg was compared to placebo (P4 implied that this recently discovered aspirin-dependent eicosanoid may be associated with the increased incidence of BOP observed in the subjects who received aspirin therapy.",
keywords = "Aspirin, Gingival crevicular fluid, Gingivitis",
author = "Kim, {David M.} and Koszeghy, {Kristian L.} and Badovinac, {Rachel L.} and Toshihisa Kawai and Ikuko Hosokawa and Howell, {T. Howard} and Karimbux, {Nadeem Y.}",
year = "2007",
month = "8",
doi = "10.1902/jop.2007.070011",
language = "English (US)",
volume = "78",
pages = "1620--1626",
journal = "Journal of Periodontology",
issn = "0022-3492",
publisher = "American Academy of Periodontology",
number = "8",

}

TY - JOUR

T1 - The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis

AU - Kim, David M.

AU - Koszeghy, Kristian L.

AU - Badovinac, Rachel L.

AU - Kawai, Toshihisa

AU - Hosokawa, Ikuko

AU - Howell, T. Howard

AU - Karimbux, Nadeem Y.

PY - 2007/8

Y1 - 2007/8

N2 - Background: Inflammatory and anti-inflammatory mediators may play a significant role in patients with gingivitis. The purpose of this study was to assess the short-term effects of the systemic administration of two different concentrations of aspirin (81 and 325 mg/day, by mouth) on clinical periodontal parameters and gingival crevicular fluid (GCF) levels of 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and interleukin (IL)-6 and -1 β in a sample of naturally occurring gingivitis patients. Methods: At day 0, after initial screening for entry, baseline periodontal parameters, including bleeding on probing (BOP), periodontal probing depths (PDs), and plaque index (PI) were measured, and GCF was sampled from 12 intrasulcular sites with filter paper strips for the measurement of six types of inflammatory and anti-inflammatory mediators using competitive enzyme immunoassay and enzyme-linked immunosorbent assay (prevalues). Forty-seven subjects were assigned randomly to one of three treatment groups: placebo (15 subjects); aspirin, 81 mg (16 subjects); and aspirin, 325 mg (16 subjects) once daily. On day 7, subjects were recalled for the measurement of periodontal parameters and collection of GCF samples for the measurement of six types of mediators (postvalues). Results: Changes in inflammatory and anti-inflammatory mediator levels were not statistically significant for any of the three treatment groups. However, when pre- and postvalues were compared in the subjects receiving aspirin, 325 mg, there was a negative trend in the relationship between 15-epi-L)(A4 and PGE2, whereas the relationship between LTB4 and PGE2 was, not as strong. This might indicate that the subjects responding to aspirin-mediated PGE2 suppression effects produced higher 15-epi-LXA4 in GCF than non-responders. No statistically significant differences in PD and PI between pre- and postvalues were found for any of the three treatment groups. However, the results demonstrated a significant increase in BOP when aspirin, 325 mg was compared to placebo (P4 implied that this recently discovered aspirin-dependent eicosanoid may be associated with the increased incidence of BOP observed in the subjects who received aspirin therapy.

AB - Background: Inflammatory and anti-inflammatory mediators may play a significant role in patients with gingivitis. The purpose of this study was to assess the short-term effects of the systemic administration of two different concentrations of aspirin (81 and 325 mg/day, by mouth) on clinical periodontal parameters and gingival crevicular fluid (GCF) levels of 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and interleukin (IL)-6 and -1 β in a sample of naturally occurring gingivitis patients. Methods: At day 0, after initial screening for entry, baseline periodontal parameters, including bleeding on probing (BOP), periodontal probing depths (PDs), and plaque index (PI) were measured, and GCF was sampled from 12 intrasulcular sites with filter paper strips for the measurement of six types of inflammatory and anti-inflammatory mediators using competitive enzyme immunoassay and enzyme-linked immunosorbent assay (prevalues). Forty-seven subjects were assigned randomly to one of three treatment groups: placebo (15 subjects); aspirin, 81 mg (16 subjects); and aspirin, 325 mg (16 subjects) once daily. On day 7, subjects were recalled for the measurement of periodontal parameters and collection of GCF samples for the measurement of six types of mediators (postvalues). Results: Changes in inflammatory and anti-inflammatory mediator levels were not statistically significant for any of the three treatment groups. However, when pre- and postvalues were compared in the subjects receiving aspirin, 325 mg, there was a negative trend in the relationship between 15-epi-L)(A4 and PGE2, whereas the relationship between LTB4 and PGE2 was, not as strong. This might indicate that the subjects responding to aspirin-mediated PGE2 suppression effects produced higher 15-epi-LXA4 in GCF than non-responders. No statistically significant differences in PD and PI between pre- and postvalues were found for any of the three treatment groups. However, the results demonstrated a significant increase in BOP when aspirin, 325 mg was compared to placebo (P4 implied that this recently discovered aspirin-dependent eicosanoid may be associated with the increased incidence of BOP observed in the subjects who received aspirin therapy.

KW - Aspirin

KW - Gingival crevicular fluid

KW - Gingivitis

UR - http://www.scopus.com/inward/record.url?scp=34548095611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548095611&partnerID=8YFLogxK

U2 - 10.1902/jop.2007.070011

DO - 10.1902/jop.2007.070011

M3 - Article

VL - 78

SP - 1620

EP - 1626

JO - Journal of Periodontology

JF - Journal of Periodontology

SN - 0022-3492

IS - 8

ER -